Search

Displaying results 3321 - 3330 of 10000 in total
  1. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.

  2. Target

    Relaxin receptor 1

    go.drugbank.com/bio_entities/BE0019700
    TargetHumans

    Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activ...

    Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 7
  3. Drug

    Lomustine

    go.drugbank.com/drugs/DB01206
    ApprovedInvestigational

    An alkylating agent of value against both hematologic malignancies and solid tumors.

    Synonyms: N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea
  4. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  5. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.

  6. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    It is not approved for use in any country, but is currently in clinical trials in the United States. … Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels.

  7. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. … Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

    Synonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
  8. Drug

    Amorolfine

    go.drugbank.com/drugs/DB09056
    ApprovedWithdrawn

    Amorolfine 5% nail lacquer in once or twice weekly applications is 60-71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment … It is not approved for the treatment of onychomycosis in the United States or Canada.

  9. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    FDA approved on March 6, 2012.

  10. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).